Impact of synbiotics on disease activity in systemic lupus erythematosus: Results from a randomized clinical trial
Journal of Food Science · 2024
DOI: 10.1111/1750-3841.17460 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Food Science, 2024. Verfasst von Zahra Mirfeizi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Synbiotics, Lupus Erythematosus, Systemic, Interleukin-17. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Mashhad University of Medical Sciences.
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects various organs in the body. In SLE, inflammatory cytokines play a crucial role in initiating and sustaining the inflammatory process. Synbiotics may help modulate these inflammatory cytokines. This randomized, double‐blind, placebo‐controlled clinical trial aimed to assess the impact of synbiotics intervention on interleukin‐17A (IL‐17A) levels, disease activity, and inflammatory factors in patients with SLE. Fifty SLE patients were randomly assigned to receive either standard therapy plus synbiotics (consisting of Streptococcus thermophilus , Lactobacillus acidophilus , Lactobacillus casei , Lactobacillus rhamnosus , Lactobacillus salivarius , Lactobacillus reuteri , Bifidobacterium lactis , Bifidobacterium longum , Bifidobacterium bifidum , and the prebiotic fructooligosaccharides) or standard therapy alone for 2 months. The results demonstrated a significant reduction in both protein and mRNA levels of IL‐17A, as well as in the Systemic Lupus Erythematosus Disease Activity Index 2000 score, within the synbiotics group after the intervention compared to baseline. In contrast, the placebo group did not experience significant changes in IL‐17A levels or disease activity. Synbiotic supplementation shows potential as an adjunctive therapeutic approach for SLE management; however, further research is needed to elucidate its underlying mechanisms. Practical Application This study explores the use of synbiotics as a supplementary treatment for systemic lupus erythematosus, which is typically managed with immunosuppressive therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Department, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Immunology and Allergy, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Clinical Research Development Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Laboratory Sciences, School of Paramedicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
ORCID-Profile: Mehdi Barati, Arezoo Faridzadeh
Förderung
- Mashhad University of Medical Sciences
Zitieren
APA
Mirfeizi, Z., Mahmoudi, M., Jokar, M. H., Sahebari, M., Noori, E., Mehrad-Majd, H., Barati, M., & Faridzadeh, A. (2024). Impact of synbiotics on disease activity in systemic lupus erythematosus: Results from a randomized clinical trial. Journal of Food Science. https://doi.org/10.1111/1750-3841.17460
Vancouver
Mirfeizi Z, Mahmoudi M, Jokar MH, Sahebari M, Noori E, Mehrad-Majd H, et al. Impact of synbiotics on disease activity in systemic lupus erythematosus: Results from a randomized clinical trial. Journal of Food Science. 2024. doi:10.1111/1750-3841.17460
BibTeX
@article{Mirfeizi2024,
author = {Mirfeizi, Zahra and Mahmoudi, Mahmoud and Jokar, Mohammad Hassan and Sahebari, Maryam and Noori, Elmira and Mehrad-Majd, Hasan and Barati, Mehdi and Faridzadeh, Arezoo},
title = {Impact of synbiotics on disease activity in systemic lupus erythematosus: Results from a randomized clinical trial},
journal = {Journal of Food Science},
year = {2024},
doi = {10.1111/1750-3841.17460}
}
EUVIMED